Updated on 5 May 2014
The collaboration is structured to increase clinical trial efficiency, with a focus on transparency, quality, innovation and operational excellence
Singapore: Quintiles and US-based biotech company Biogen Idec have entered into a five-year strategic clinical development agreement.
The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes.
According to Quintiles' media statement, the collaboration is structured to increase clinical trial efficiency, with a focus on transparency, quality, innovation and operational excellence.
"Our partnership with Biogen Idec exemplifies the ongoing evolution of drug development collaboration and reinforces the increasingly important role that biopharmaceutical service providers such as Quintiles have in these efforts," said Mr Tom Pike, chief executive officer, Quintiles.
"We are extremely excited about this agreement and the increased interest we are seeing for these types of innovative development deals. We believe Quintiles is uniquely positioned to help our customers improve their probability of success through these collaborations, and we look forward to working closely with Biogen Idec."